Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrogen peroxide and povidone-iodine gargling for SARS-CoV-2 salivary viral load reduction
IRCT20201212049681N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of povidone-iodine and hydrogen peroxide in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Shiraz University of Medical Sciences. Started Jan 2021; status: completed.
02
Drugs
povidone-iodinehydrogen peroxide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20201212049681N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201212049681N1.